Reuters logo
BRIEF-Sanofi, Regeneron say Cemiplimab receives U.S. FDA breakthrough designation for advanced cutaneous squamous cell carcinoma
2017年9月8日 / 凌晨5点08分 / 3 个月前

BRIEF-Sanofi, Regeneron say Cemiplimab receives U.S. FDA breakthrough designation for advanced cutaneous squamous cell carcinoma

Sept 8 (Reuters) -

* Sanofi, Regeneron: Cemiplimab receives FDA breakthrough designation for advanced cutaneous squamous cell carcinoma

* Sanofi - pending data results, co and Regeneron anticipate submitting a biologics license application for Cemiplimab with the FDA in Q1 2018

* Sanofi - Cemiplimab is currently under clinical development, its safety and efficacy has not been fully evaluated by any regulatory authority Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below